Associations between Antibodies to a Panel of Plasmodium falciparum Specific Antigens and Response to Sub-Optimal Antimalarial Therapy in Kampala, Uganda

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Keh, Chris E ^a   Jha, Aashish R ^a,e   Nzarubara, Bridget ^b   Lanar, David E ^c   Dutta, Sheetij ^c   Theisen, Michael ^d   Rosenthal, Philip J ^a   Dorsey, Grant ^a   Nixon, Douglas F ^a   Greenhouse, Bryan ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b INFECTIOUS DISEASES RESEARCH COLLABORATION   (Uganda)

^c WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^d STATENS SERUM INSTITUT   (Denmark)

^e UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; ANTIMALARIAL AGENT; APICAL MEMBRANE ANTIGEN 1; IMMUNOGLOBULIN G ANTIBODY; PARASITE ANTIGEN; PLASMODIUM FALCIPARUM ANTIGEN; PYRIMETHAMINE PLUS SULFADOXINE; UNCLASSIFIED DRUG;

ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIMICROBIAL THERAPY; ARTICLE; BLOOD SAMPLING; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DRUG TREATMENT FAILURE; HUMAN; HUMAN CELL; IMMUNITY; INFECTION PREVENTION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; PARASITE CLEARANCE; PLASMODIUM FALCIPARUM; PRESCHOOL CHILD; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SCHOOL CHILD; TREATMENT RESPONSE; UGANDA;

ANTIBODIES, PROTOZOAN; ANTIBODY FORMATION; ANTIGENS, PROTOZOAN; ANTIMALARIALS; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; SPECIES SPECIFICITY; TREATMENT OUTCOME; UGANDA;

PLASMODIUM FALCIPARUM;

EID: 84871315016     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052571     Document Type: Article

References (41)

1. World Health Organization (2011) World Malaria Report 2011. Geneva: World Health Organization. Available: http://www.who.int/malaria/world_malaria_report_2011/en. Accessed 2012 June 1.
2. Cohen S, McGregor IA, Carrington S, (1961) Gamma-globulin and acquired immunity to human malaria. Nature 192: 733-737.
3. McGregor IA, Carrington SP, Cohen S, (1963) Treatment of East African P. falciparum malaria with West African human gamma-globulin. Transactions of the Royal Society of Tropical Medicine and Hygiene 57: 170-175.
4. Fowkes FJ, Richards JS, Simpson JA, Beeson JG, (2010) The relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: A systematic review and meta-analysis. PLoS Med 7: e1000218 doi:10.1371/journal.pmed.1000218.
5. Crompton PD, Kayala MA, Traore B, Kayentao K, Ongoiba A, et al. (2010) A prospective analysis of the Ab response to Plasmodium falciparum before and after a malaria season by protein microarray. Proc Natl Acad Sci U S A 107: 6958-6963 doi:10.1073/pnas.1001323107.
6. Osier FH, Fegan G, Polley SD, Murungi L, Verra F, et al. (2008) Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria. Infect Immun 76: 2240-2248 doi:10.1128/IAI.01585-07.
7. Kinyanjui SM, Bejon P, Osier FH, Bull PC, Marsh K, (2009) What you see is not what you get: implications of the brevity of antibody responses to malaria antigens and transmission heterogeneity in longitudinal studies of malaria immunity. Malar J 8: 242 doi:10.1186/1475-2875-8-242.
8. Bejon P, Warimwe G, Mackintosh CL, Mackinnon MJ, Kinyanjui SM, et al. (2009) Analysis of immunity to febrile malaria in children that distinguishes immunity from lack of exposure. Infect Immun 77: 1917-1923 doi:10.1128/IAI.01358-08.
9. Greenhouse B, Ho B, Hubbard A, Njama-Meya D, Narum DL, et al. (2011) Antibodies to Plasmodium falciparum antigens predict a higher risk of malaria but protection from symptoms once parasitemic. J Infect Dis 204: 19-26 doi:10.1093/infdis/jir223.
10. Djimdé AA, Doumbo OK, Traore O, Guindo AB, Kayentao K, et al. (2003) Clearance of drug-resistant parasites as a model for protective immunity in Plasmodium falciparum malaria. Am J Trop Med Hyg 69: 558-563.
11. Rogerson SJ, Wijesinghe RS, Meshnick SR, (2010) Host immunity as a determinant of treatment outcome in Plasmodium falciparum malaria. Lancet Infect Dis 10: 51-59 doi:10.1016/S1473-3099(09)70322-6.
12. Greenhouse B, Slater M, Njama-Meya D, Nzarubara B, Maiteki-Sebuguzi C, et al. (2009) Decreasing efficacy of antimalarial combination therapy in Uganda is explained by decreasing host immunity rather than increasing drug resistance. J Infect Dis 199: 758-765 doi:10.1086/596741.
13. Egan AF, Morris J, Barnish G, Allen S, Greenwood BM, et al. (1996) Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1. J Infect Dis 173: 765-769.
14. Nebie I, Diarra A, Ouedraogo A, Soulama I, Bougouma EC, et al. (2008) Humoral responses to Plasmodium falciparum blood-stage antigens and association with incidence of clinical malaria in children living in an area of seasonal malaria transmission in Burkina Faso, West Africa. Infect Immun 76: 759-766 doi:10.1128/IAI.01147-07.
15. Polley SD, Mwangi T, Kocken CH, Thomas AW, Dutta S, et al. (2004) Human antibodies to recombinant protein constructs of Plasmodium falciparum Apical Membrane Antigen 1 (AMA1) and their associations with protection from malaria. Vaccine 23: 718-728 doi:10.1016/j.vaccine.2004.05.031.
16. John CC, Tande AJ, Moormann AM, Sumba PO, Lanar DE, et al. (2008) Antibodies to pre-erythrocytic Plasmodium falciparum antigens and risk of clinical malaria in Kenyan children. J Infect Dis 197: 519-526 doi:10.1086/526787.
17. Dorsey G, Staedke S, Clark TD, Njama-Meya D, Nzarubara B, et al. (2007) Combination therapy for uncomplicated falciparum malaria in Ugandan children: a randomized trial. JAMA 297: 2210-2219 doi:10.1001/jama.297.20.2210.
18. Clark TD, Njama-Meya D, Nzarubara B, Maiteki-Sebuguzi C, Greenhouse B, et al. (2010) Incidence of Malaria and Efficacy of Combination Antimalarial Therapies over 4 Years in an Urban Cohort of Ugandan Children. PLoS One 5: e11759 doi:10.1371/journal.pone.0011759.
19. Severe falciparum malaria. World Health Organization, Communicable Diseases Cluster (2000) Trans R Soc Trop Med Hyg. 94Suppl 1: S1-90 doi:11103309.
20. Greenhouse B, Dokomajilar C, Hubbard A, Rosenthal PJ, Dorsey G, (2007) Impact of transmission intensity on the accuracy of genotyping to distinguish recrudescence from new infection in antimalarial clinical trials. Antimicrob Agents Chemother 51: 3096-3103 doi:10.1128/AAC.00159-07.
21. Global report on antimalarial drug efficacy and drug resistance 2000-2010. (2010). Geneva, Switzerland: World Health Organization. p. Available: http://whqlibdoc.who.int/publications/2010/9789241500470_eng.pdf. Accessed 20 June 2012.
22. Dutta S, Lalitha PV, Ware LA, Barbosa A, Moch JK, et al. (2002) Purification, characterization, and immunogenicity of the refolded ectodomain of the Plasmodium falciparum apical membrane antigen 1 expressed in Escherichia coli. Infection and immunity 70: 3101 doi:10.1128/IAI.70.6.3101-3110.2002.
23. Kaslow D, Hu G, Kumar S, (1994) Expression and antigenicity of Plasmodium falciparum major merozoite surface protein (MSP1-19) variants secreted from Saccharomyces cerevisiae. Mol Biochem Parasitol 63: 283-289.
24. al-Yaman F, Genton B, Anders RF, Falk M, Triglia T, et al. (1994) Relationship between humoral response to Plasmodium falciparum merozoite surface antigen-2 and malaria morbidity in a highly endemic area of Papua New Guinea. Am J Trop Med Hyg 51: 593-602.
25. Carvalho LJ, Oliveira SG, Theisen M, Alves FA, Andrade MCR, et al. (2004) Immunization of Saimiri sciureus monkeys with Plasmodium falciparum merozoite surface protein-3 and glutamate-rich protein suggests that protection is related to antibody levels. Scand J Immunol 59: 363-372 doi:10.1111/j.0300-9475.2004.01409.x.
26. Theisen M, Vuust J, Gottschau A, Jepsen S, Høgh B, (1995) Antigenicity and immunogenicity of recombinant glutamate-rich protein of Plasmodium falciparum expressed in Escherichia coli. Clin Diagn Lab Immunol 2: 30-34.
27. Clark TD, Greenhouse B, Njama-Meya D, Nzarubara B, Maiteki-Sebuguzi C, et al. (2008) Factors determining the heterogeneity of malaria incidence in children in Kampala, Uganda. J Infect Dis 198: 393-400 doi:10.1086/589778.
28. Verret WJ, Dorsey G, Nosten F, Price RN, (2009) The effect of varying analytical methods on estimates of anti-malarial clinical efficacy. Malaria Journal 8: 77 doi:10.1186/1475-2875-8-77.
29. R Development Core Team (2009) R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing. p. Available: http://www.R-project.org.
30. Thera MA, Doumbo OK, Coulibaly D, Laurens MB, Ouattara A, et al. (2011) A field trial to assess a blood-stage malaria vaccine. N Engl J Med 365: 1004-1013 doi:10.1056/NEJMoa1008115.
31. Mayxay M, Chotivanich K, Pukrittayakamee S, Newton P, Looareesuwan S, et al. (2001) Contribution of humoral immunity to the therapeutic response in falciparum malaria. Am J Trop Med Hyg 65: 918-923.
32. Aubouy A, Migot-Nabias F, Deloron P, (2007) Correlations between treatment outcome and both anti-MSP119 antibody response and erythrocyte-related genetic factors in Plasmodium falciparum malaria. Infect Genet Evol 7: 147-154 doi:10.1016/j.meegid.2006.07.001.
33. Pinder M, Sutherland CJ, Sisay-Joof F, Ismaili J, McCall MBB, et al. (2006) Immunoglobulin G antibodies to merozoite surface antigens are associated with recovery from chloroquine-resistant Plasmodium falciparum in Gambian children. Infect Immun 74: 2887-2893 doi:10.1128/IAI.74.5.2887-2893.2006.
34. Mawili-Mboumba DP, Borrmann S, Cavanagh DR, McBride JS, Matsiegui P-BB, et al. (2003) Antibody responses to Plasmodium falciparum merozoite surface protein-1 and efficacy of amodiaquine in Gabonese children with P. falciparum malaria. J Infect Dis 187: 1137-1141 doi:10.1086/368414.
35. Feng G, Aitken E, Yosaatmadja F, Kalilani L, Meshnick SR, et al. (2009) Antibodies to variant surface antigens of Plasmodium falciparum-infected erythrocytes are associated with protection from treatment failure and the development of anemia in pregnancy. J Infect Dis 200: 299-306 doi:10.1086/599841.
36. Enevold A, Nkya WM, Theisen M, Vestergaard LS, Jensen AT, et al. (2007) Potential impact of host immunity on malaria treatment outcome in Tanzanian children infected with Plasmodium falciparum. Malar J 6: 153 doi:10.1186/1475-2875-6-153.
37. Van Geertruyden JP, Van Eijk E, Yosaatmadja F, Kasongo W, Mulenga M, et al. (2009) The relationship of Plasmodium falciparum humeral immunity with HIV-1 immunosuppression and treatment efficacy in Zambia. Malar J 8: 258 doi:10.1186/1475-2875-8-258.
38. Diarra A, Nebie I, Tiono A, Soulama I, Ouedraogo A, et al. (2012) Antibodies to malaria vaccine candidates are associated with chloroquine or sulphadoxine/pyrimethamine treatment efficacy in children in an endemic area of Burkina Faso. Malar J 11: 79 doi:10.1186/1475-2875-11-79.
39. Robert V, Roeffen W, Brasseur P, Aribot G, Verhave JP, et al. (2000) Anti-NANP antibody and treatment efficacy in patients with acute uncomplicated falciparum malaria attacks. Parasite Immunol 22: 589-593.
40. Uthaipibull C, Aufiero B, Syed SE, Hansen B, Guevara Patiño JA, et al. (2001) Inhibitory and blocking monoclonal antibody epitopes on merozoite surface protein 1 of the malaria parasite Plasmodium falciparum. J Mol Biol 307: 1381-1394 doi:10.1006/jmbi.2001.4574.
41. Nwuba RI, Sodeinde O, Anumudu CI, Omosun YO, Tiono AB, et al. (2002) The human immune response to Plasmodium falciparum includes both antibodies that inhibit merozoite surface protein 1 secondary processing and blocking antibodies. Infection and Immunity 70: 5328-5331 doi:10.1128/IAI.70.9.5328-5331.2002.